Literature DB >> 21396745

Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors.

Zhangyu Yao1, Xueying Wei, Xiaoming Wu, Jonathan L Katz, Theresa Kopajtic, Nigel H Greig, Hongbin Sun.   

Abstract

Tetrabenazine (TBZ) ((±)-1) and dihydrotetrabenazines (DHTBZ) are potent inhibitors of VMAT2. Herein, a practical chemical resolution of (±)-1 and stereoselective synthesis of all eight DHTBZ stereoisomers are described. The result of VMAT2 binding assay revealed that (+)-1 (Ki=4.47 nM) was 8000-fold more potent than (-)-1 (Ki=36,400 nM). Among all eight DHTBZ stereoisomers, (2R,3R,11bR)-DHTBZ ((+)-2: Ki=3.96 nM) showed the greatest affinity for VMAT2. The (3R,11bR)-configuration appeared to play a key role for VMAT2 binding. In summary, (+)-1, (+)-2, and their derivatives warrant further studies in order to develop more potent and safer drugs for the treatment of chorea associated with Huntington's disease and other hyperkinetic disorders.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21396745      PMCID: PMC6191844          DOI: 10.1016/j.ejmech.2011.02.046

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  12 in total

1.  Hydrophobicity of the tetrabenazine-binding site of the chromaffin granule monoamine transporter.

Authors:  D Scherman; B Gasnier; P Jaudon; J P Henry
Journal:  Mol Pharmacol       Date:  1988-01       Impact factor: 4.436

Review 2.  Emerging drugs in Tourette syndrome.

Authors:  Yavuz S Silay; Joseph Jankovic
Journal:  Expert Opin Emerg Drugs       Date:  2005-05       Impact factor: 4.191

3.  Metabolic studies of tetrabenazine, a psychotropic drug in animals and man.

Authors:  D E Schwartz; H Bruderer; J Rieder; A Brossi
Journal:  Biochem Pharmacol       Date:  1966-05       Impact factor: 5.858

4.  Absolute configuration of (+)-alpha-dihydrotetrabenazine, an active metabolite of tetrabenazine.

Authors:  M R Kilbourn; L C Lee; M J Heeg; D M Jewett
Journal:  Chirality       Date:  1997       Impact factor: 2.437

5.  Preparation and Characterization of Tetrabenazine Enantiomers against Vesicular Monoamine Transporter 2.

Authors:  Qian-Sheng Yu; Weiming Luo; Jeffery Deschamps; Harold W Holloway; Theresa Kopajtic; Jonathan L Katz; Arnold Brossi; Nigel H Greig
Journal:  ACS Med Chem Lett       Date:  2010-03-31       Impact factor: 4.345

6.  Pyrrolidine analogues of lobelane: relationship of affinity for the dihydrotetrabenazine binding site with function of the vesicular monoamine transporter 2 (VMAT2).

Authors:  Ashish P Vartak; Justin R Nickell; Jaturaporn Chagkutip; Linda P Dwoskin; Peter A Crooks
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

Review 7.  Tetrabenazine.

Authors:  Alfonso Fasano; Anna Rita Bentivoglio
Journal:  Expert Opin Pharmacother       Date:  2009-12       Impact factor: 3.889

8.  Asymmetric synthesis of tetrabenazine and dihydrotetrabenazine.

Authors:  Michael J Rishel; Kande K D Amarasinghe; Sean R Dinn; Bruce F Johnson
Journal:  J Org Chem       Date:  2009-05-15       Impact factor: 4.354

9.  In vitro and in vivo studies of benzisoquinoline ligands for the brain synaptic vesicle monoamine transporter.

Authors:  L C Lee; T Vander Borght; P S Sherman; K A Frey; M R Kilbourn
Journal:  J Med Chem       Date:  1996-01-05       Impact factor: 7.446

10.  The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders.

Authors:  M S Roberts; S McLean; K S Millingen; H M Galloway
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more
  9 in total

Review 1.  The vesicular monoamine transporter 2: an underexplored pharmacological target.

Authors:  Alison I Bernstein; Kristen A Stout; Gary W Miller
Journal:  Neurochem Int       Date:  2014-01-04       Impact factor: 3.921

2.  Derivatization of (±) dihydrotetrabenazine for copper-64 labeling towards long-lived radiotracers for PET imaging of the vesicular monoamine transporter 2.

Authors:  Amit Kumar; Su-Tang Lo; Orhan K Öz; Xiankai Sun
Journal:  Bioorg Med Chem Lett       Date:  2014-10-28       Impact factor: 2.823

3.  Synthesis of (±)-Tetrabenazine by Visible Light Photoredox Catalysis.

Authors:  Lindsey R Orgren; Emily E Maverick; Christopher C Marvin
Journal:  J Org Chem       Date:  2015-11-13       Impact factor: 4.354

Review 4.  VMAT2 Inhibitors in Neuropsychiatric Disorders.

Authors:  Arjun Tarakad; Joohi Jimenez-Shahed
Journal:  CNS Drugs       Date:  2018-12       Impact factor: 5.749

5.  Redox-Annulation of Cyclic Amines and β-Ketoaldehydes.

Authors:  Weijie Chen; Daniel Seidel
Journal:  Org Lett       Date:  2016-02-19       Impact factor: 6.005

6.  Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine.

Authors:  Heather Skor; Evan B Smith; Gordon Loewen; Christopher F O'Brien; Dimitri E Grigoriadis; Haig Bozigian
Journal:  Drugs R D       Date:  2017-09

7.  Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect.

Authors:  Frank Schneider; David Stamler; Margaret Bradbury; Pippa S Loupe; Edward Hellriegel; Donna S Cox; Juha-Matti Savola; Mark Forrest Gordon; Laura Rabinovich-Guilatt
Journal:  Clin Pharmacol Drug Dev       Date:  2020-10-10

Review 8.  Synthesis of Tetrabenazine and Its Derivatives, Pursuing Efficiency and Selectivity.

Authors:  Seung-Mann Paek
Journal:  Molecules       Date:  2020-03-05       Impact factor: 4.411

9.  (+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia.

Authors:  Wenyan Wang; Guangying Du; Shilan Lin; Jing Liu; Huijie Yang; Dawei Yu; Liang Ye; Fangxia Zou; Hongbo Wang; Rui Zhang; Jingwei Tian
Journal:  Front Pharmacol       Date:  2021-12-07       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.